Loading
A phase 2 trial of Gemcitabine, Oxaliplatin and TQB2825 in non-Hodgkin lymphoma, run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., now recruiting.
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma is a phase 2 interventional study registered as NCT06854445 by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., with 55 participants planned, started 2025-03-12 and due to reach its primary completion in 2025-10. Interventions recorded: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Gemcitabine and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Oxaliplatin and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Oxaliplatin, Gemcitabine and the tag pipeline.